Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.
about
HITlights: a career perspective on heparin-induced thrombocytopeniaGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismHIT paradigms and paradoxes.Immunogenic but effective: the HIT-fondaparinux brain puzzler.Management of heparin-induced thrombocytopenia.Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: a case report.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia.Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman.Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinuxDesign of the rivaroxaban for heparin-induced thrombocytopenia study.A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients.Progressive thrombocytopenia after cardiac surgery in a 67-year-old man.Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia.Prevention of venous thromboembolism in the Enhanced Recovery After Surgery (ERAS) setting: an evidence-based review.Venous thromboembolism in cancer patients.A case of probable bemiparin-induced HIT type II managed with low-dose fondaparinuxEfficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia.Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism.Evidence-based guidance on venous thromboembolism in patients with solid tumoursCancer-associated thrombosis: an overviewAutoimmune heparin-induced thrombocytopenia.Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?Superficial vein thrombosis.Management of pulmonary embolism: state of the art treatment and emerging research.Acquired Thrombophilia.Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials
P2860
Q26828351-79D70CBE-8FCB-4FF7-9EF9-FF6ECAC90D3AQ28079081-F5919798-FD26-4CF2-B02F-B34DE2070C1BQ33396313-CE2FE544-2327-4E47-920E-3520A2D670DBQ33397282-ACEDB5C0-C526-41C1-8D07-C601472E42F5Q33400573-10E98DC2-71CA-4516-AE12-BC60880D008BQ33403703-98FAF7AC-3B9E-4737-B82E-81AB6DC69490Q33406618-ECC26701-050D-4F18-886D-D8C5D71357BBQ33407198-9EE6F5BA-8A0A-4D93-8C53-F5095F3ACB2CQ33408471-33A850DC-2E4E-4ED9-991D-5EDEFEE16B2EQ33408949-1AB7F5C3-A24E-46D6-9E2B-F85CC1A732F1Q33410578-ADB2CD28-686D-48EF-9EA7-987473F737ADQ33413409-1084DE4F-13DE-4931-A164-8DC03285C9AAQ33414139-484F5808-671C-433B-97A5-5CA3A502B7CAQ33414796-3593DE93-9586-49D2-8B6F-2D23A2A34A53Q33414886-ECC47D38-170D-431E-9447-27A74DE714D5Q33418678-B4FA9D06-51ED-44DD-9B03-3D1380C2B1E9Q33419213-6DB59D87-733D-482B-9B64-2A1D0171439EQ33421168-53BD5979-019A-4E54-9362-0EDBF6130186Q33432234-54AD27E9-7EC0-4478-8EEC-C82E2986398AQ33440222-8C99CD99-6460-4630-AB24-F263F9349099Q33440296-040879D5-028C-4724-B8D1-6902341B19CCQ33442488-AB785EAF-C4C7-474C-9604-473576311691Q33763946-24732C10-7C1A-449E-9941-A16219A1C807Q34655217-8524F39C-F496-4277-B60A-6D9BCBA817B3Q38605630-4EA3E593-8483-4A69-8917-EEB351E82D52Q43065983-03DDE492-FE2D-49B2-8C6F-28F7403B0973Q43905870-CEB791E3-9DAF-4B0B-BE68-3B5EFCBC84ECQ44304204-3E9E34B1-22D9-48AF-894C-DD775AC42828Q51846266-79ED5219-7FAD-4ECC-B66C-2E4543915A29Q57824209-54B18991-DBB3-436A-B76F-3DD5190CFFBA
P2860
Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fondaparinux treatment of acut ...... month, 16-patient case series.
@ast
Fondaparinux treatment of acut ...... month, 16-patient case series.
@en
type
label
Fondaparinux treatment of acut ...... month, 16-patient case series.
@ast
Fondaparinux treatment of acut ...... month, 16-patient case series.
@en
prefLabel
Fondaparinux treatment of acut ...... month, 16-patient case series.
@ast
Fondaparinux treatment of acut ...... month, 16-patient case series.
@en
P2860
P50
P921
P1476
Fondaparinux treatment of acut ...... month, 16-patient case series.
@en
P2093
A C Spyropoulos
J I Sheppard
P2860
P304
P356
10.1111/J.1538-7836.2011.04487.X
P577
2011-12-01T00:00:00Z